Protalix BioTherapeutics (PLX) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Protalix BioTherapeutics (PLX) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
84.25% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
-10.84% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
26.38% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
34.98% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-46.86% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
13.80% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Protalix BioTherapeutics |
176.47 Mn |
165.67 Mn |
29.62 Mn |
98.74% |
| Date | Value |
|---|
| Mar 31, 2026 |
98.74% |
| Dec 31, 2025 |
-10.34% |
| Sep 30, 2025 |
38.85% |
| Jun 30, 2025 |
27.53% |
| Mar 31, 2025 |
-16.55% |
| Dec 31, 2024 |
53.74% |
| Sep 30, 2024 |
40.16% |
| Jun 30, 2024 |
42.13% |
| Mar 31, 2024 |
7.79% |
| Dec 31, 2023 |
-330.66% |
| Sep 30, 2023 |
25.92% |
| Jun 30, 2023 |
80.39% |
| Mar 31, 2023 |
-60.55% |
| Dec 31, 2022 |
-213.86% |
| Sep 30, 2022 |
0.25% |
| Jun 30, 2022 |
11.69% |
| Mar 31, 2022 |
32.56% |
| Dec 31, 2021 |
-6.13% |
| Sep 30, 2021 |
8.20% |
| Jun 30, 2021 |
-10.02% |
